FDA-Approved Targeted Therapies in Oncology

  • George Louis KumarEmail author


Targeted therapies serve as a foundation for precision medicine. Unlike traditional chemotherapy which affects all cells in the body, the drugs used in targeted therapies block only the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth. Because targeted therapy is precise, the damage to healthy cells is minimal resulting in fewer side effects than standard chemotherapy. This chapter will highlight targeted therapies approved by the US “Food and Drug Administration” commonly referred to as the FDA. Specifically, agents that target cell signaling pathways, therapies that stop the growth of hormone-sensitive tumors, angiogenesis inhibitors that block blood vessel growth to cancers, antibody-drug conjugates or radioactively attached antibody particles, immunotherapies that trigger or reactivate the body’s immune system, epigenetic drugs that inhibit enzymes, and proteasome inhibitors will be highlighted.


Targeted therapy FDA Oncology Monoclonal antibodies Antibody-drug conjugates Immunotherapies Epigenetic drugs Proteasome inhibitors Small-molecule inhibitor 


  1. 1.
    U.S. Food and Drug Administration. Countries and Regions Covered by OIP Offices. . Accessed 16 Dec 2016.
  2. 2.
    Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008;44(1):30–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    American Society of Clinical Oncology. Cancer Progress Timeline. Accessed 16 Dec 2016.
  4. 4.
    Rahma OE, Kunk PR, Khleif SN. In: Khleif S, Rixe O, Skeel RT, editors. Skeel’s handbook of cancer therapy. 9th ed. Philadelphia: Wolters Kluver; 2016. p. 17–62.Google Scholar
  5. 5.
    List of therapeutic monoclonal antibodies. Wikipedia. Accessed 21 Dec 2016.
  6. 6.
    Carter PJ. Antibody drug nomenclature: what is INN a name? WHO has been changing them? Antibody Engineering & Therapeutics, Dec. 9th 2015. San Diego, CA. Accessed 21 Dec 2016.
  7. 7.
    Jones TD, Carter PJ, Plückthun A, et al. The INNs and outs of antibody nonproprietary names. MAbs. 2016;8(1):1–9.CrossRefGoogle Scholar
  8. 8.
    OncoKB. OncoKB Team. Accessed 19 Mar 2017.
  9. 9.
    Cancer Research UK. Your cancer type. Accessed 19 Mar 2017.
  10. 10.
    Weisber E, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7:345–56.CrossRefGoogle Scholar
  11. 11.
    Alberts B, Johnson A, Lewis J, et al. Cancer. In: Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, editors. Molecular biology of the cell. 5th ed. New York: Garland Science; 2008. p. 1205–67.Google Scholar
  12. 12.
    Seyfizadeh N, et al. A molecular perspective on rituximab: a monoclonal antibody for B-cell non-Hodgkin lymphoma and other affections. Crit Rev Oncol/Hematol. 2016;97:275–90.CrossRefGoogle Scholar
  13. 13.
    Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Peddi PF, Hurvitz SA. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013;9(3) Scholar
  15. 15.
    Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–70.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Anchoori RK, Karanam B, Peng S, et al. A bis-Benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. 2013;24(6):791–805.CrossRefGoogle Scholar
  17. 17.
  18. 18.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Targos Inc.IssaquahUSA

Personalised recommendations